The following is a continuation of all our recent MindMed coverage.
Last week, we published the first conversation with Jake Freeman.
Before that, it all began with a two-part interview with Dr. Scott Freeman in August.
Jake Freeman’s Letter to MindMed CEO, Robert Barrow
As this MindMed ($MNMD) story builds, our very own Adam Tubero continues to sit at the center of the coverage. If he is chosen to moderate a potential debate between these two, you better believe we’ll do what we can to make it the best debate possible.
Below is the latest conversation with Jake Freeman AFTER he issued this letter on Monday.
During this follow-up conversation, Adam and Jake discuss MindMed’s alleged mishandling of intellectual property, their management team, their pathway to profitability, and much more including leaked court documents.
There’s Still More To Come
This story remains a fluid and volatile one. Please keep checking back as we unearth more breaking news and insights (and possibly a debate). No spoilers, but we may even have more news to release before the end of the week.
Follow on the Psychedelic Invest YouTube Channel